Experimental drug poziotinib tested for Hard-to-Treat lung cancer
NCT ID NCT03066206
First seen Nov 11, 2025 · Last updated Jun 11, 2026 · Updated 32 times
Summary
This study tested a drug called poziotinib in 93 people with advanced non-small cell lung cancer that had specific gene mutations (EGFR or HER2). The goal was to see if the drug could shrink tumors. The study was stopped early, but it aimed to provide a new treatment option for patients who had run out of standard therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.